GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Inventories, Raw Materials & Components

Kyverna Therapeutics (Kyverna Therapeutics) Inventories, Raw Materials & Components : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Inventories, Raw Materials & Components?

Kyverna Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2024 was $0.00 Mil.


Kyverna Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Kyverna Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Inventories, Raw Materials & Components Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Inventories, Raw Materials & Components
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Inventories, Raw Materials & Components Get a 7-Day Free Trial - - - - -

Kyverna Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines